Clinical trial
A Phase 3b, Long-Term, Observational Study of the Durability of Seroconversion in Patients With Chronic Hepatitis B Virus Infection Who Have Seroconverted While Participating in a Previous Gilead-Sponsored Study of Adefovir Dipivoxil.
NCT00158717 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Long-Term, Observational Study of the Durability of Seroconversion in Patients With Chronic Hepatitis B Virus Infection Who Have Seroconverted While Participating in a Previous Gilead-Sponsored Study of Adefovir Dipivoxil.
- Lead sponsor
- Gilead Sciences
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 30, 2003
- Completion date
- April 30, 2006
- Enrollment
- 107 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.